FibroGen, Inc. presented data from a China-based Phase II study of roxadustat (FG-4592), its first-in-class oral compound for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia. Roxadustat is an orally administered, small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase. HIF is a protein that responds to oxygen changes i...